Epigenetic therapy is a novel method in oncology which addresses reversible epigenetic gene expression changes for cancer therapy. The session "Epigenetic Therapy" addresses methodologies to modulate DNA methylation, histone adjustment, and non-coding RNAs to regulate tumor growth and development.".
Cancer cells usually develop epigenetic changes that inactivate tumor suppressor genes or activate oncogenes. In contrast with genetic mutations, these alterations are reversible, offering specific therapeutic possibilities. Epigenetic drugs are intended to restore normal gene function, increase sensitivity to traditional therapy, and prevent drug resistance. The examples are DNA methyltransferase inhibitors, histone deacetylase inhibitors, and new RNA-based therapies.
The session also examines combination approaches, combining epigenetic therapy with chemotherapy, immunotherapy, or targeted therapy to enhance results. Progress in molecular profiling, biomarker discovery, and high-throughput screening is enabling the identification of patients most likely to derive benefit from these interventions.
The audience will learn about epigenetic therapy mechanisms, clinical use, and current research. This session highlights the promise of epigenetic targetability to create novel, personalized, and efficient cancer therapies for offering new hope to patients with resistant or challenging-to-treat cancers.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
